Cancer Clinical Research Unit Trials

Click on trial for description and contact information.

 

Minority-Based Community Clinical Oncology Program trials.

Advanced Solid Malignancies

• Study of XL184 in Adults with Advanced Solid Tumors
   
  
• A Phase I Open-Label, Sequential Dose Escalation Study Investigating the Safety, Tolerability, and Pharmacokinetics of Intravenous Lipotecan® (TLC388 HCl for Injection) when administered to Patients with Advanced Solid Tumors
   
  
  
  
• Study of the Safety and Pharmacokinetics of XL147 in Adults With Solid Tumors or Lymphoma
   
  

Breast Cancer

• Study of XL184 in Adults with Advanced Solid Tumors
   
  
• A Phase I Open-Label, Sequential Dose Escalation Study Investigating the Safety, Tolerability, and Pharmacokinetics of Intravenous Lipotecan® (TLC388 HCl for Injection) when administered to Patients with Advanced Solid Tumors
   
  
  
  

Blood Cancers

• Safety and Efficacy of RAD001 in Patients With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Velcade® Therapy. (PILLAR-1)
   
  
• A Phase 1/1b Study of TRU-016 in Patients With Chronic Lymphocytic Leukemia or Select Subtypes of Non-Hodgkin’s Lymphoma
   
  
• Dose Finding Study of Panobinostat Given in Combination With 5-Azacitidine in Patients With MDS, CMML or AML
   
  
• Study of the Safety and Pharmacokinetics of XL147 in Adults With Solid Tumors or Lymphoma
   
  
• Safety and Efficacy of Panobinostat in Primary Myelofibrosis
   
  
• Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma (PANORAMA II)
   
  
• Phase II Study of Oral Panobinostat in Adult Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma (This study is ongoing but currently not recruiting patients.)
   
  
• A Phase 2, multi-center, open-label, exploratory study of Bcr-Abl kinetics in adult patients on nilotinib with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP) and a suboptimal molecular response to imatinib
   
  
• A single arm, phase II, open-label study to determine the efficacy of 100mg twice daily oral dosing of Midostaurin administered to patients with Aggressive Systemic Mastocytosis or Mast Cell Leukemia +/- an Associated Hematological Clonal Non-Mast Cell Lineage Disease
   
  

Chest and Lung Cancer

• Study of XL184 in Adults with Advanced Solid Tumors
   
  
• A Phase I Open-Label, Sequential Dose Escalation Study Investigating the Safety, Tolerability, and Pharmacokinetics of Intravenous Lipotecan® (TLC388 HCl for Injection) when administered to Patients with Advanced Solid Tumors
   
  
  
  

Gastrointestinal Cancer

• Study of XL184 in Adults with Advanced Solid Tumors
   
  
• A Phase I Open-Label, Sequential Dose Escalation Study Investigating the Safety, Tolerability, and Pharmacokinetics of Intravenous Lipotecan® (TLC388 HCl for Injection) when administered to Patients with Advanced Solid Tumors
   
  
  
  

Genitourinary / Prostate Cancer

• Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma (RECORD3)
   
  
• Study of XL184 in Adults with Advanced Solid Tumors
   
  
• A Phase I Open-Label, Sequential Dose Escalation Study Investigating the Safety, Tolerability, and Pharmacokinetics of Intravenous Lipotecan® (TLC388 HCl for Injection) when administered to Patients with Advanced Solid Tumors
   
  
•  Phase 3, Randomized, Double-Blind Trial to Compare the Efficacy of Ipilimumab vs Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naïve Castration Resistant Prostate Cancer.
   
  
  
  

Gynecologic Cancer

• Study of XL184 in Adults with Advanced Solid Tumors
   
• A Phase I Open-Label, Sequential Dose Escalation Study Investigating the Safety, Tolerability, and Pharmacokinetics of Intravenous Lipotecan® (TLC388 HCl for Injection) when administered to Patients with Advanced Solid Tumors
   
  
• Study of XL147 in Advanced or Recurrent Endometrial Cancer
   
  
•  
  

Skin Cancer

• Study of XL184 in Adults with Advanced Solid Tumors
   
  
• A Phase I/II, open-label, dose escalation trial to evaluate the safety, Pharmacokinetics, and Pharmacodynamics of RAF265 (CHIR-265) administered orally to patients with locally advanced or Metastatic Melanoma
   
  

 

[Back to Top]